Agustin Resendiz-Sharpe

Dr. Agustin Resendiz-Sharpe

KU Leuven
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2018 in Medical Mycology
Verified
Journal Article
Closed access
PDF file
Agustin Resendiz-SharpeAgustin Resendiz-Sharpe
Agustin Resendiz-Sharpe
KLKatrien Lagrou
Katrien Lagrou
JMJacques F Meis
Jacques F Meis
ACAnuradha Chowdhary
Anuradha Chowdhary
SLShawn R Lockhart
Shawn R Lockhart
OGon behalf of the ISHAM/ECMM Aspergillus Resistance Surveillance working group
on behalf of the ISHAM/ECMM Aspergillus Resistance Surveillance working group
Triazole resistance is an increasing concern in the opportunistic mold Aspergillus fumigatus. Resistance can develop through exposure to azole compounds during azole therapy or in the environment. Resistance mutations are commonly found in the Cyp51A-gene, although other known and unknown resistance mechanisms may be present. Surveillance studies show triazole resistance in six continents, although the presence of resistance remains unknown in many countries. In most countries, resistance mutations associated with the environment dominate, but it remains unclear if these resistance traits predominately migrate or arise locally. Patients with triazole-resistant aspergillus disease may fail to antifungal therapy, but only a limited number of cohort studies have been performed that show conflicting results. Treatment failure might be due to diagnostic delay or due to the limited number of alternative treatment options. The ISHAM/ECMM Aspergillus Resistance Surveillance working group was set up to facilitate surveillance studies and stimulate international collaborations. Important aims are to determine the resistance epidemiology in countries where this information is currently lacking, to gain more insight in the clinical implications of triazole resistance through a registry and to unify nomenclature through consensus definitions.

24 June 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
Agustin Resendiz-SharpeAgustin Resendiz-Sharpe
Agustin Resendiz-Sharpe
TMToine Mercier
Toine Mercier
PLPieter P A Lestrade
Pieter P A Lestrade
MBMartha T van der Beek
Martha T van der Beek
PBPeter A von Dem Borne
Peter A von Dem Borne
KLKatrien Lagrou
Katrien Lagrou
Background: Increasing resistance of Aspergillus fumigatus to triazoles in high-risk populations is a concern. Its impact on mortality is not well understood, but rates from 50% to 100% have been reported. Objectives: To determine the prevalence of voriconazole-resistant A. fumigatus invasive aspergillosis (IA) and its associated mortality in a large multicentre cohort of haematology patients with culture-positive IA. Methods: We performed a multicentre retrospective study, in which outcomes of culture-positive haematology patients with proven/probable IA were analysed. Patients were stratified based on the voriconazole susceptibility of their isolates (EUCAST broth microdilution test). Mycological and clinical data were compared, along with survival at 6 and 12 weeks. Results: We identified 129 A. fumigatus culture-positive proven or probable IA cases; 103 were voriconazole susceptible (79.8%) and 26 were voriconazole resistant (20.2%). All but one resistant case harboured environment-associated resistance mutations in the cyp51A gene: TR34/L98H (13 cases) and TR46/Y121F/T289A (12 cases). Triazole monotherapy was started in 75.0% (97/129) of patients. Mortality at 6 and 12 weeks was higher in voriconazole-resistant cases in all patients (42.3% versus 28.2%, P = 0.20; and 57.7% versus 36.9%, P = 0.064) and in non-ICU patients (36.4% versus 21.6%, P = 0.16; and 54.4% versus 30.7%; P = 0.035), compared with susceptible ones. ICU patient mortality at 6 and 12 weeks was very high regardless of triazole susceptibility (75.0% versus 66.7%, P = 0.99; and 75.0% versus 73.3%, P = 0.99). Conclusions: A very high prevalence of voriconazole resistance among culture-positive IA haematology patients was observed. The overall mortality at 12 weeks was significantly higher in non-ICU patients with voriconazole-resistant IA compared with voriconazole-susceptible IA.

29 April 2020 in mSphere
Verified
Journal Article
Open access
PDF file
RBRafael Wesley Bastos
Rafael Wesley Bastos
CVClara Valero
Clara Valero
LSLilian Pereira Silva
Lilian Pereira Silva
TSTaylor Schoen
Taylor Schoen
MDMilton Drott
Milton Drott
Gustavo Henrique GoldmanGustavo Henrique Goldman
Gustavo Henrique Goldman
Immunocompromised patients are susceptible to infections with opportunistic filamentous fungi from the genus Aspergillus . Although A. fumigatus is the main etiological agent of Aspergillus species-related infections, other species, such as A. nidulans , are prevalent in a condition-specific manner. A. nidulans is a predominant infective agent in patients suffering from chronic granulomatous disease (CGD). A. nidulans isolates have mainly been studied in the context of CGD although infection with A. nidulans also occurs in non-CGD patients. This study carried out a detailed biological characterization of two non-CGD A. nidulans clinical isolates and compared the results to those with a reference strain. Phenotypic, metabolomic, and genomic analyses highlight fundamental differences in carbon source utilization, stress responses, and maintenance of cell wall integrity among the strains. One clinical strain had increased virulence in models with impaired neutrophil function. Just as in A. fumigatus , strain heterogeneity exists in A. nidulans clinical strains that can define virulence traits.

21 September 2021 in Virulence
Verified
Journal Article
Open access
LSLaura Seldeslachts
Laura Seldeslachts
LVLore Vanderbeke
Lore Vanderbeke
AFAstrid Fremau
Astrid Fremau
Agustin Resendiz-SharpeAgustin Resendiz-Sharpe
Agustin Resendiz-Sharpe
CJCato Jacobs
Cato Jacobs
Greetje Vande VeldeGreetje Vande Velde
Greetje Vande Velde
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection occurring mainly in immunocompromised patients. We recently identified IPA as an emerging co-infection with high mortality in critically ill, but otherwise immunocompetent influenza patients. The neuraminidase inhibitor oseltamivir is the current standard-of-care treatment in hospitalized influenza patients; however, its efficacy in influenza-associated pulmonary aspergillosis (IAPA) is not known. Therefore, we have established an imaging-supported double-hit mouse model to investigate the therapeutic effect of oseltamivir on the development of IAPA. Immunocompetent mice received intranasal instillation influenza A or PBS followed by orotracheal inoculation with Aspergillus fumigatus 4 days later. Oseltamivir treatment or placebo was started at day 0, day 2, or day 4. Daily monitoring included micro-computed tomography and bioluminescence imaging of pneumonia and fungal burden. Non-invasive biomarkers were complemented with imaging, molecular, immunological, and pathological analysis. Influenza virus-infected immunocompetent mice developed proven airway IPA upon co-infection with Aspergillus fumigatus, whereas non-influenza-infected mice fully cleared Aspergillus, confirming influenza as a risk factor for developing IPA. Longitudinal micro-CT showed pulmonary lesions after influenza infection worsening after Aspergillus co-infection, congruent with bioluminescence imaging and histology confirming Aspergillus pneumonia. Early oseltamivir treatment prevented severe influenza pneumonia and mitigated the development of IPA and associated mortality. A time-dependent treatment effect was consistently observed with imaging, molecular, and pathological analyses. Hence, our findings underscore the importance of initiating oseltamivir as soon as possible, to suppress influenza infection and mitigate the risk of potentially lethal IAPA disease.

12 April 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Agustin Resendiz-SharpeAgustin Resendiz-Sharpe
Agustin Resendiz-Sharpe
KDKlaas Dewaele
Klaas Dewaele
RMRita Merckx
Rita Merckx
BBBeatriz Bustamante
Beatriz Bustamante
MGMaría Celeste Vega Gómez
María Celeste Vega Gómez
Katrien LagrouKatrien Lagrou
Katrien Lagrou
Triazole-resistance has been reported increasingly in Aspergillus fumigatus. An international expert team proposed to avoid triazole monotherapy for the initial treatment of invasive aspergillosis in regions with >10% environmental-resistance, but this prevalence is largely unknown for most American and African countries. Here, we screened 584 environmental samples (soil) from urban and rural locations in Mexico, Paraguay, and Peru in Latin America and Benin and Nigeria in Africa for triazole-resistant A. fumigatus. Samples were screened using triazole-containing agars and confirmed as triazole-resistant by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth dilution reference method. Isolates were further characterized by cyp51A sequencing and short-tandem repeat typing. Fungicide presence in samples was likewise determined. Among A. fumigatus positive samples, triazole-resistance was detected in 6.9% (7/102) of samples in Mexico, 8.3% (3/36) in Paraguay, 9.8% (6/61) in Peru, 2.2% (1/46) in Nigeria, and none in Benin. Cyp51A gene mutations were present in most of the triazole-resistant isolates (88%; 15/17). The environmentally-associated mutations TR34/L98H and TR46/Y121F/T289A were prevalent in Mexico and Peru, and isolates harboring these mutations were closely related. For the first time, triazole-resistant A. fumigatus was found in environmental samples in Mexico, Paraguay, Peru, and Nigeria with a prevalence of 7–10% in the Latin American countries. Our findings emphasize the need to establish triazole-resistance surveillance programs in these countries.

1 May 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
IDIntan Mauli Warma Dewi
Intan Mauli Warma Dewi
CCCristina Cunha
Cristina Cunha
MJMartin Jaeger
Martin Jaeger
MGMark S. Gresnigt
Mark S. Gresnigt
MGMarina E. Gkountzinopoulou
Marina E. Gkountzinopoulou
FVFrank van de Veerdonk
Frank van de Veerdonk
Influenza-associated pulmonary aspergillosis (IAPA) has been reported increasingly since the advent of use of neuraminidase (NA) inhibitors following the 2009 influenza pandemic. We hypothesize that blocking host NA modulates the immune response against Aspergillus fumigatus. We demonstrate that NA influences the host response against A. fumigatus in vitro and that oseltamivir increases the susceptibility of mice to pulmonary aspergillosis. Oseltamivir impairs the mouse splenocyte and human peripheral blood mononuclear cell (PBMC) killing capacity of A. fumigatus, and adding NA restores this defect in PBMCs. Furthermore, the sialic acid-binding receptor SIGLEC15 is upregulated in PBMCs stimulated with A. fumigatus. Silencing of SIGLEC15 decrease PBMC killing of A. fumigatus. We provide evidence that host NA activity and sialic acid recognition are important for anti-Aspergillus defense. NA inhibitors might predispose individuals with severe influenza to invasive aspergillosis. These data shed light on the pathogenesis of invasive fungal infections and may identify potential therapeutic targets.